person · Reporting owner
Fairmount Healthcare Co-Invest III L.P.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Oruka Therapeutics, Inc.ORKA · Entity 3781 | Director · 10% owner | July 01, 2026 | July 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Oruka Therapeutics, Inc.
Report date July 01, 2026 · Filed July 02, 2026
Jointly reported with Fairmount Funds Management LLC, Fairmount Healthcare Fund II L.P., Kiselak Tomas, Harwin Peter Evan
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Fairmount Healthcare Fund II L.P. | 1,131,954 |
Last balance in matching sequence
After 2026-07-01 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2026-07-01 · Conversion · Acquired 3,553,410 · Balance 4,685,364 F1: Each share of Series B Preferred Stock is convertible at the option of the holder into 83.3332 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. On July 1, 2026, the Reporting Persons converted 42,641 shares of Series B Preferred Stock into 3,553,410 shares of Common Stock for no cash consideration, in accordance with the Certificate of Designation for the Series B Convertible Preferred Stock. F2: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest III L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. Row 2 · 2026-07-01 · Sale · Disposed 3,553,410 · Balance 1,131,954 F2: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest III L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. |
| Series B Preferred StockSEC Table II · derivative / convertible security | IndirectBy Fairmount Healthcare Fund II L.P. | 94,497 |
Reported balance
After 2026-07-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-07-01 · Conversion · Disposed 42,641 · Balance 94,497 F1: Each share of Series B Preferred Stock is convertible at the option of the holder into 83.3332 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. On July 1, 2026, the Reporting Persons converted 42,641 shares of Series B Preferred Stock into 3,553,410 shares of Common Stock for no cash consideration, in accordance with the Certificate of Designation for the Series B Convertible Preferred Stock. F2: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest III L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Fairmount Healthcare Co-Invest III L.P. | 2,573,308 |
Reported balance
Holding disclosure · report date 2026-07-01 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 2,573,308 F2: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest III L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of Series B Preferred Stock is convertible at the option of the holder into 83.3332 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. On July 1, 2026, the Reporting Persons converted 42,641 shares of Series B Preferred Stock into 3,553,410 shares of Common Stock for no cash consideration, in accordance with the Certificate of Designation for the Series B Convertible Preferred Stock.
F2: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest III L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 01, 2026 Filed Jul 2, 2026 01:30 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | ConversionSeries B Preferred Stock · Derivative | 42,641 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-080009 · tm2619616-1_4seq1.xml · derivative · entry 4 Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner Fairmount Healthcare Co-Invest III L.P. · CIK 0002009690 · Director · 10% owner Kiselak Tomas · CIK 0001830177 · Director · 10% owner Harwin Peter Evan · CIK 0001663607 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Fairmount Healthcare Fund II L.P. Disclosed balance after: 94,497 Underlying: Common Stock · 3,553,410 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series B Preferred Stock is convertible at the option of the holder into 83.3332 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. On July 1, 2026, the Reporting Persons converted 42,641 shares of Series B Preferred Stock into 3,553,410 shares of Common Stock for no cash consideration, in accordance with the Certificate of Designation for the Series B Convertible Preferred Stock. F1 · derivative.exercise_date: Each share of Series B Preferred Stock is convertible at the option of the holder into 83.3332 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. On July 1, 2026, the Reporting Persons converted 42,641 shares of Series B Preferred Stock into 3,553,410 shares of Common Stock for no cash consideration, in accordance with the Certificate of Designation for the Series B Convertible Preferred Stock. F1 · derivative.expiration_date: Each share of Series B Preferred Stock is convertible at the option of the holder into 83.3332 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. On July 1, 2026, the Reporting Persons converted 42,641 shares of Series B Preferred Stock into 3,553,410 shares of Common Stock for no cash consideration, in accordance with the Certificate of Designation for the Series B Convertible Preferred Stock. F2 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest III L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 01:30 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | SaleCommon Stock | 3,553,410 | $84.43 | $300,014,406.30 |
DisclosureSEC source: 0001104659-26-080009 · tm2619616-1_4seq1.xml · nonDerivative · entry 2 Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner Fairmount Healthcare Co-Invest III L.P. · CIK 0002009690 · Director · 10% owner Kiselak Tomas · CIK 0001830177 · Director · 10% owner Harwin Peter Evan · CIK 0001663607 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Fairmount Healthcare Fund II L.P. Disclosed balance after: 1,131,954 F2 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest III L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. Read SEC document |
| July 01, 2026 Filed Jul 2, 2026 01:30 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | ConversionCommon Stock | 3,553,410 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-26-080009 · tm2619616-1_4seq1.xml · nonDerivative · entry 1 Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner Fairmount Healthcare Co-Invest III L.P. · CIK 0002009690 · Director · 10% owner Kiselak Tomas · CIK 0001830177 · Director · 10% owner Harwin Peter Evan · CIK 0001663607 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Fairmount Healthcare Fund II L.P. Disclosed balance after: 4,685,364 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series B Preferred Stock is convertible at the option of the holder into 83.3332 shares of Common Stock, subject to certain beneficial ownership limitations, including that a holder of Series B Preferred Stock is prohibited from converting shares of Series B Preferred Stock into shares of Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 19.99% of the total number of shares of Common Stock issued and outstanding immediately after giving effect to such conversion. On July 1, 2026, the Reporting Persons converted 42,641 shares of Series B Preferred Stock into 3,553,410 shares of Common Stock for no cash consideration, in accordance with the Certificate of Designation for the Series B Convertible Preferred Stock. F2 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest III L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. Read SEC document |
| June 02, 2026 Filed Jun 3, 2026 20:45 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | GrantStock Option (Right to Buy) · Derivative | 9,136 | $0.00 Strike: $55.23 | $0.00 |
DisclosureSEC source: 0001104659-26-070135 · tm2616798-1_4seq1.xml · derivative · entry 1 Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner Fairmount Healthcare Co-Invest III L.P. · CIK 0002009690 · Director Harwin Peter Evan · CIK 0001663607 · Director · 10% owner Kiselak Tomas · CIK 0001830177 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By: Peter Harwin Disclosed balance after: 9,136 Underlying: Common Stock · 9,136 shares Expires 2036-06-01 F1 · derivative.exercise_date: This option represents a right to purchase 9,136 shares of the Issuer's common stock, which vests as to 1/12 of the option monthly from June 2, 2026, subject to the recipient's continued service to the Issuer. F2 · ownership.direct: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II LP ("Fund II") and Fairmount Healthcare Co-Invest III L.P. ("Co-Invest"). Peter Harwin and Tomas Kiselak are the managers of Fairmount. Under Mr. Harwin's arrangement with Fairmount, Mr. Harwin holds the option for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Harwin is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. Read SEC document |
| September 17, 2025 Filed Sep 19, 2025 21:33 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | GrantCommon Stock | 333,340 | $15.00 | $5,000,100.00 |
DisclosureSEC source: 0001104659-25-091747 · tm2526585-1_4seq1.xml · nonDerivative · entry 1 Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner Fairmount Healthcare Co-Invest III L.P. · CIK 0002009690 · Director · 10% owner Kiselak Tomas · CIK 0001830177 · Director · 10% owner Harwin Peter Evan · CIK 0001663607 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By Fairmount Healthcare Fund II L.P. Disclosed balance after: 1,131,954 F1 · kind: The shares of Common Stock were purchased from the Issuer in a private placement, which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended. F2 · ownership.nature: Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fairmount Healthcare Fund II L.P. and Fairmount Healthcare Co-Invest III L.P. The managers of Fairmount are Peter Harwin and Tomas Kiselak. Fairmount, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. Read SEC document |
| June 02, 2025 Filed Jun 3, 2025 20:30 UTC | Oruka Therapeutics, Inc. ORKA · Entity 3781 | GrantStock Option (Right to Buy) · Derivative | 17,500 | $0.00 Strike: $11.77 | $0.00 |
DisclosureSEC source: 0001104659-25-055989 · tm2517029-1_4seq1.xml · derivative · entry 1 Fairmount Funds Management LLC · CIK 0001802528 · Director · 10% owner Fairmount Healthcare Fund II L.P. · CIK 0001769651 · Director · 10% owner Fairmount Healthcare Co-Invest III L.P. · CIK 0002009690 · Director Harwin Peter Evan · CIK 0001663607 · Director · 10% owner Kiselak Tomas · CIK 0001830177 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By: Peter Harwin Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2035-06-01 F1 · derivative.exercise_date: This option represents a right to purchase 17,500 shares of the Issuer's common stock, which vests as to 1/12 of the option monthly from June 2, 2025, subject to the recipient's continued service to the Issuer. F2 · ownership.direct: Under Mr. Harwin's arrangement with Fairmount Funds Management LLC ("Fairmount"), Mr. Harwin holds the option for one or more investment vehicles managed by Fairmount (each, a "Fairmount Fund"). Mr. Harwin is obligated to turn over to Fairmount any net cash or stock received from the option for the benefit of such Fairmount Fund. Mr. Harwin therefore disclaims beneficial ownership of the option and underlying common stock. Fairmount disclaims beneficial ownership of any of the reported securities, except to the extent of its pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.